Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Bercolagene Telserpavec (KB103), a Non-Integrating, Replication-Incompetent Herpes Simplex Virus 1 (HSV-1) Vector Expressing the Human Collagen VII (COL7) Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)

Trial Profile

A Phase II Study of Bercolagene Telserpavec (KB103), a Non-Integrating, Replication-Incompetent Herpes Simplex Virus 1 (HSV-1) Vector Expressing the Human Collagen VII (COL7) Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs KB 103 (Primary)
  • Indications Epidermolysis bullosa
  • Focus First in man; Therapeutic Use
  • Acronyms GEM-1
  • Sponsors Krystal Biotech
  • Most Recent Events

    • 19 Dec 2019 According to a Krystal Biotech media release, four patients have been dosed.
    • 23 Oct 2018 Primary endpoint has been changed and hence trial focus has changed. Planned patient number of patients has been increased.
    • 23 Oct 2018 Planned number of patients changed from 6 to 4.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top